CanSino's independently developed 13-valent pneumococcal polysaccharide conjugate vaccine PCV13i and Asia's first quadrivalent meningococcal polysaccharide conjugate vaccine MCV4 were shipped to the domestic and overseas markets respectively.
CanSino Biologics' independently developed 13-valent pneumococcal polysaccharide conjugate vaccine, Upexin®, was officially approved by the National Medical Products Administration in June of this year. It is China's first pneumococcal polysaccharide conjugate vaccine to utilize a dual vector consisting of an avirulent mutant of diphtheria toxin (CRM197) and tetanus toxoid (TT). This vaccine provides enhanced protection against the four serotypes (19F, 19A, 7F, and 3) that carry the heaviest burden of pneumococcal disease in children in China. It is reported that by 2026, Upexin® will expand its reach into the domestic market, with overseas expansion also in the works.
When Youpexin® was shipped domestically, Asia's first ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) Manhaixin® also departed from Tianjin and was sent to Indonesia. This is also the second time that CanSino's vaccine products have been exported after the new crown vaccine.
As the first domestically developed and the third global quadrivalent meningococcal polysaccharide conjugate vaccine available for infants under 6 months of age, Manhaixin® is steadily advancing its internationalization process. The product was approved in Indonesia in December 2024 and received Halal certification from Indonesia in February of this year. Furthermore, the company is currently conducting clinical trials in Indonesia to evaluate the safety and immunogenicity of Manhaixin® following vaccination in people aged 18-55, with a view to expanding the product's applicable population. In addition to promoting its entry into the Indonesian market, CanSino Biologics also formally signed a vaccine cooperation agreement with its Saudi Arabian partner in March of this year. The two parties will work together to accelerate Manhaixin®'s entry into Saudi Arabia and other Middle East and North African markets, and promote joint R&D and the establishment of a localized production system.

https://finance.eastmoney.com/a/202509303527536427.html